<DOC>
	<DOCNO>NCT01051219</DOCNO>
	<brief_summary>This randomize , control trial determine whether Losartan effective slowing , halt reverse liver fibrosis patient non-alcoholic steatohepatitis ( NASH ) . Liver fibrosis accumulation tough , fibrous scar tissue liver occur patient NASH . NASH resemble alcoholic liver disease , occur people drink little alcohol . The major feature NASH fat liver , along inflammation damage , may lead cirrhosis , liver permanently damage scar longer able function properly . Primary hypothesis : That losartan superior placebo reversing , slow halt fibrosis patient non-alcoholic fatty liver disease , 24 month treatment . Secondary hypothesis : 1 . That safety profile angiotensin receptor blocker ( losartan ) patient population acceptable 2 . That losartan prevent clinical deterioration non-alcoholic fatty liver disease 3 . That serum , radiological histological marker fibrosis correlate patient 24 month period</brief_summary>
	<brief_title>Anti-Fibrotic Effects Losartan In Nash Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Adults ( male female , age 18+ ) steatohepatitis fibrosis ( Kleiner F1F3 ) , result nonalcoholic fatty liver disease . Refusal inability ( lack capacity ) give inform consent Average alcohol ingestion &gt; 21 units/week ( male ) &gt; 14 units/week ( female ) History presence Type 1 diabetes mellitus Haemoglobin A1C &gt; 15.0 Other cause chronic liver disease hepatic steatosis Any contraindication liver biopsy History , plan , gastrointestinal bypass surgery Hepatocellular carcinoma Previous liver transplantation Recent significant weight loss ( &gt; 5 % total body weight within last 6 month ) Electrolyte disturbance : potassium level outside normal ( local ) range Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 10 x upper limit normal ( ULN ) screen Recent ( within 6 month baseline liver biopsy screen visit ) concomitant use agent know cause hepatic steatosis ( corticosteroid , amiodarone , methotrexate , tamoxifen , tetracycline , high dose oestrogen , valproic acid ) , concomitant use pioglitazone , fluconazole , rifampicin drug contraindicate Losartan SmPC Introduction metformin , glitazones , GLP1 agonist , Vitamin E C , betaine , sadenosyl methionine , ursodeoxycholic acid , silymarin , fibrate , pentoxifylline , orlistat , sibutramine rimonabant within 3 month baseline liver biopsy screen visit Intolerance angiotensin receptor blocker ( ARBs ) presence multiple allergic reaction drug Use angiotensinconverting enzyme ( ACE ) inhibitor ARB previous year Hypotension ( systolic &lt; 100 , diastolic &lt; 60 ) Renal failure ( Cr &gt; 130 ) Participation clinical study investigational agent within 30 day five halflives investigational product , whichever long Presence clinically relevant cardiovascular , pulmonary , gastrointestinal , renal , hepatic , metabolic , haematological , neurological , psychiatric , systemic , ocular , gynaecologic acute infectious disease sign acute illness , opinion investigator , might compromise patient 's safe participation trial Presence history cancer within past 5 year exception adequately treat localized basal cell carcinoma skin , situ cervical carcinoma solid malignancy surgically excise toto without recurrence five year Women childbearing potential protected effective contraceptive method birth control surgical sterilization and/or unwilling unable test pregnancy ( Pregnancy status check serum pregnancy test initiation study treatment urine pregnancy test trial ) Known allergy sensitivity losartan excipients ( microcrystalline cellulose [ E460 ] ; lactose monohydrate ; pregelitanized maize starch ; magnesium stearate [ E572 ] ; hydroxypropyl cellulose [ E463 ] ; hypromellose [ E464 ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Losartan</keyword>
	<keyword>Liver fibrosis</keyword>
	<keyword>Nonalcoholic steatohepatitis</keyword>
</DOC>